Bruce Eaton’s Eye of Apps and Tech Making Travel More Enjoyable
Dr. Eaton travels the globe in search of new opportunities for i2 Pharmaceuticals and Velocity Sciences. His work and his personal travels have taken him to western Europe, Mexico, Argentina, Chile, Australia, New Zealand, Singapore, and Japan. He hopes to visit China in the near future. Bruce Eaton is the president and chief executive officer of i2 Pharmaceuticals, Inc., a hit discovery and lead optimization technology provider serving clients in the pharmaceutical industry. In addition, Bruce Eaton is the president and chief executive officer of Velocity Sciences, a developer of next-generation assay technologies for the diagnostics industry. As he travels the world he is constantly looking for technology that enhances the experience.
Dr. Eaton formerly served as the chief operating officer of SomaLogic, Inc., a proteomics technology company offering life sciences tools to clients such as Quest, Otsuka, and Novartis. In addition to handling the company’s corporate strategic planning efforts, he facilitated corporate communications and directed business development. Dr. Eaton has served as a consultant to a wide variety of therapeutic and diagnostic life science companies during his three decades in biotechnology.
Bruce Eaton holds a PhD in organic chemistry from the University of California, Berkeley. He has secured 35 patents in the United States and more than 80 global patents in chemistry, biochemistry, and medicinal chemistry. Currently, he is a board member of Galaxy Ophthalmics, the Colorado BioScience Association and the Colorado Institute for Drug, Device and Diagnostic Development.
Dr. Eaton formerly served as the chief operating officer of SomaLogic, Inc., a proteomics technology company offering life sciences tools to clients such as Quest, Otsuka, and Novartis. In addition to handling the company’s corporate strategic planning efforts, he facilitated corporate communications and directed business development. Dr. Eaton has served as a consultant to a wide variety of therapeutic and diagnostic life science companies during his three decades in biotechnology.
Bruce Eaton holds a PhD in organic chemistry from the University of California, Berkeley. He has secured 35 patents in the United States and more than 80 global patents in chemistry, biochemistry, and medicinal chemistry. Currently, he is a board member of Galaxy Ophthalmics, the Colorado BioScience Association and the Colorado Institute for Drug, Device and Diagnostic Development.